Do indications to sublingual immunotherapy need to be revised?

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 1-3, 2010, Pages 277-

  Incorvaia, Cristoforo ^a   Mauro, Marina ^b  

^a ICP Hospital   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GRASS POLLEN VACCINE; IMMUNOMODULATING AGENT; STALLERGEN; STALORAL; UNCLASSIFIED DRUG;

ANAPHYLAXIS; BRONCHUS DISEASE; BRONCHUS REACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IMMUNOTHERAPY; LETTER; NOSE DISEASE; PRIORITY JOURNAL; SUBLINGUAL IMMUNOTHERAPY; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ALLERGENS; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 77956172923     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.10.033     Document Type: Letter

References (5)

1. Cochard M.M., and Eigenmann P.A. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. J Allergy Clin Immunol 124 (2009) 378-379
2. de Groot H., and Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 64 (2009) 963-964
3. Ariano R., Incorvaia C., La Grutta S., Marcucci F., Pajno G., Sensi L., et al. Safety of sublingual immunotherapy started during the pollen season. Curr Med Res Opin 25 (2009) 103-107
4. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W., et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118 (2006) 434-440
5. Alvarez-Cuesta E., Bousquet J., Canonica G.W., Durham S.R., Malling H.J., and Valovirta E. EAACI Immunotherapy Task Force. Standards for practical allergen-specific immunotherapy. Allergy 61 suppl 82 (2006) 1-20